非酒精性脂肪性肝炎所致晚期纤维化的自然史:来自Simtuzumab试验的数据
分析475例非酒精性脂肪性肝炎伴桥接纤维化(F3)或代偿性肝硬化(F4)患者,来自两项2b期安慰剂对照Simtuzumab试验,因缺乏疗效于96周终止后合并治疗组数据。F3患者进展为肝硬化的比例为22%(48/217),F4患者发生肝脏相关临床事件的比例为19%(50/258)。纤维化及其随时间变化是临床疾病进展的主要决定因素。
要点
- F3患者进展为肝硬化的比例为22%(48/217),F4患者肝脏相关临床事件发生率为19%(50/258)。
- 基线肝胶原含量、α-平滑肌肌动蛋白水平及增强肝纤维化评分较高且增加更显著,与进展为肝硬化显著相关。
- 肝硬化患者中,纤维化分期未改善(风险比9.30;95%置信区间1.28-67.37)与肝脏相关临床事件风险增加相关。
核心结论
- 在非酒精性脂肪性肝炎所致晚期纤维化患者中,临床疾病进展的主要决定因素是纤维化及其随时间的变化。
研究设计与样本
- 分析两项2b期、安慰剂对照Simtuzumab试验中475例非酒精性脂肪性肝炎伴桥接纤维化(F3)或代偿性肝硬化(F4)患者的数据;试验因缺乏疗效于96周终止,故合并治疗组数据。
主要发现
- F3患者进展为肝硬化的比例为22%(48/217),F4患者发生肝脏相关临床事件的比例为19%(50/258)。
- 与进展为肝硬化显著相关的因素包括基线肝胶原含量、α-平滑肌肌动蛋白水平及增强肝纤维化评分较高,以及这些指标增加更显著。
- 肝硬化患者中,类似因素外加纤维化分期未改善(风险比9.30;95%置信区间1.28-67.37)、基线肝静脉压力梯度较高及肝静脉压力梯度随时间增加更显著,与肝脏相关临床事件风险增加相关。
- 调整纤维化分期后,疾病进展与基线非酒精性脂肪性肝病活动度评分或治疗期间该评分变化无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridging fibrosis (F3) or compensated cirrhosis (F4) enrolled in two phase 2b, placebo-controlled trials of simtuzumab. The trials were terminated after 96 weeks because of lack of efficacy, so data from treatment groups were combined. Liver biopsies and HVPG measurements (only for patients with F4 fibrosis) were collected at screening and at weeks 48 and 96. Patients were assessed for Ishak fibrosis stage, hepatic collagen content and alpha-smooth muscle actin (by morphometry), NAFLD Activity Score (NAS), and serum markers of fibrosis. Associations with progression to cirrhosis (in patients with F3 fibrosis) and liver-related clinical events (in patients with F4 fibrosis) were determined. Progression to cirrhosis occurred in 22% (48/217) of F3 patients, and liver-related clinical events occurred in 19% (50/258) of patients with cirrhosis. Factors significantly associated with progression to cirrhosis included higher baseline values of and greater increases in hepatic collagen content, level of alpha-smooth muscle actin, and Enhanced Liver Fibrosis score. Similar factors, plus lack of fibrosis stage improvement (hazard ratio, 9.30; 95% confidence interval, 1.28-67.37), higher HVPG at baseline, and greater increase in HVPG over time, were associated with an increased risk of liver-related clinical events in patients with cirrhosis. Disease progression was not associated with the NAS at baseline or changes in NAS during treatment after adjustment for fibrosis stage. Conclusion: In patients with advanced fibrosis due to NASH, the primary determinant of clinical disease progression is fibrosis and its change over time.
引用
- Sanyal AJ, Harrison SA, Ratziu V, et al. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019. PMID: 30993748. doi:10.1002/hep.30664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。